ethinyl estradiol/norelgestromin transdermal contraceptive — Competitive Intelligence Brief

ethinyl estradiol/norelgestromin transdermal contraceptive (ethinyl estradiol/norelgestromin transdermal contraceptive) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormonal contraceptive. Area: Contraception.

marketed Hormonal contraceptive Estrogen receptor and progesterone receptor Contraception Small molecule

Target snapshot

ethinyl estradiol/norelgestromin transdermal contraceptive (ethinyl estradiol/norelgestromin transdermal contraceptive) — University of Pittsburgh. Ethinyl estradiol and norelgestromin suppress ovulation by inhibiting the luteinizing hormone surge and thickening cervical mucus, preventing pregnancy.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ethinyl estradiol/norelgestromin transdermal contraceptive TARGET	ethinyl estradiol/norelgestromin transdermal contraceptive	University of Pittsburgh	marketed	Hormonal contraceptive	Estrogen receptor and progesterone receptor
ethinyl estradiol/etonogestrel vaginal ring	ethinyl estradiol/etonogestrel vaginal ring	University of Pittsburgh	marketed	Combined hormonal contraceptive	Estrogen receptor and progesterone receptor
placebo + ethinylestradiol/levonorgestrel	placebo + ethinylestradiol/levonorgestrel	HRA Pharma	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor
Ethinylestradiol / Norethisterone	Ethinylestradiol / Norethisterone	University of Edinburgh	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor
Estradiol valerate / dienogest	Estradiol valerate / dienogest	Helsinki University Central Hospital	marketed	Oral contraceptive (combined estrogen-progestin)	Estrogen receptor and progesterone receptor
Ethinyl Estradiol / Norgestimate Oral Tablet	Ethinyl Estradiol / Norgestimate Oral Tablet	University of Colorado, Denver	marketed	Oral contraceptive (combined estrogen-progestin)	Estrogen receptor and progesterone receptor
ETHINYL ESTRADIOL AND LEVOGESTREL	ETHINYL ESTRADIOL AND LEVOGESTREL	FHI 360	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormonal contraceptive class)

1. Penn State University · 2 drugs in this class
2. Italfarmaco · 1 drug in this class
3. Kayseri Education and Research Hospital · 1 drug in this class
4. TherapeuticsMD · 1 drug in this class
5. University of Alabama at Birmingham · 1 drug in this class
6. University of Athens · 1 drug in this class
7. FHI 360 · 1 drug in this class
8. University of Pittsburgh · 1 drug in this class